Ligand Pharmaceuticals(NASDAQ) LGND

Ligand Pharmaceuticals Incorporated helps drug makers create new medicines for patients. It earns money when partners sell these treatments to the public. The company focuses on buying rights to future drug payments.

Medicines and Money

• Royalty Interests: Income earned from partner sales of approved drugs; includes rights to more than 200 pharmaceutical programs.
• Captisol Technology: Chemical tool used to stabilize medicines; sold directly to partners to help the human body absorb drugs.
• Development Financing: Capital provided to partners for drug trials; creates future royalty streams from high-value medicines.

How Is Ligand Growing?

• Acquired XOMA Royalty on July 14, 2026, to double the size of its royalty portfolio.
• Issued $700.0 million in convertible senior notes on June 25, 2026, to fund future investments.
• Fulfilled a $15 million payment to Orchestra BioMed on May 6, 2026, under a royalty-based agreement.
• Entered a sales agreement on Feb. 27, 2026, to potentially sell up to $100.0 million in common stock.

What Makes Ligand Different?

Ligand functions as a specialized financier that provides capital to pharmaceutical companies in exchange for future sales shares. This model allows the business to benefit from medical breakthroughs without maintaining expensive labs or sales teams.

A Look at the Ledger

• Total revenue and income rose 34% year over year to $63.7 million in Q2 2026.
• Royalty revenue grew 42% year over year to $91.0 million for the six-month period ended June 30, 2026.
• Operating income was $26.0 million in the first half of 2026, up from a $27.8 million loss in 2025.
• Cash and short-term investments totaled $1.4 billion as of June 30, 2026, following a major debt offering.
• General and administrative expenses increased 44% year over year to $29.1 million in Q2 2026.

Bottom Line

Ligand has evolved into a royalty company that funds medical innovation while avoiding the heavy costs of manufacturing. Its growing portfolio of commercial assets and technical platforms provides a foundation for steady cash flows.